This article is more than 5 years old. Information may no longer be current.

FDA announces extended supply shortage of mechlorethamine HCI

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The FDA was recently informed that there will be an extended supply shortage of mechlorethamine HCI for injection (Mustargen, Lundbeck Inc).

A limited supply of mechlorethamine HCI is expected to be available in mid-April, with priority given to facilities including patients who currently receive the drug. However, when this supply is depleted, the manufacturer anticipates a shortage until the beginning of 2011.

The FDA recommended that pharmacies and physicians’ offices notify their distributor to obtain the drug on a drop ship basis only in order to meet patient needs when it is released in mid-April. FDA officials added that in order to avoid an interruption to treatment with mechlorethamine HCI, an alternative treatment plan should be made for new patients.

No other supplies of the drug are available from any other source at this time. For more information about the shortage, visit Drugshortages@fda.hhs.gov.

Follow HemOncToday.com on Twitter.